NO325346B1 - Anvendelse av 1-ar(alk)yl-imidazolin-2-on for behandling av angst- og spenningstilstander - Google Patents
Anvendelse av 1-ar(alk)yl-imidazolin-2-on for behandling av angst- og spenningstilstander Download PDFInfo
- Publication number
- NO325346B1 NO325346B1 NO19995300A NO995300A NO325346B1 NO 325346 B1 NO325346 B1 NO 325346B1 NO 19995300 A NO19995300 A NO 19995300A NO 995300 A NO995300 A NO 995300A NO 325346 B1 NO325346 B1 NO 325346B1
- Authority
- NO
- Norway
- Prior art keywords
- anxiety
- compounds
- treatment
- general formula
- alkyl
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims description 18
- 230000036506 anxiety Effects 0.000 title claims description 14
- 238000011282 treatment Methods 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 14
- 230000000949 anxiolytic effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 239000002249 anxiolytic agent Substances 0.000 description 7
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 6
- 229960003120 clonazepam Drugs 0.000 description 6
- 229960003529 diazepam Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229960002225 medazepam Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000037321 sleepiness Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940125713 antianxiety drug Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 208000012802 recumbency Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- ADOLLNOHUDQRCE-UHFFFAOYSA-N 1-(4-chlorophenyl)-4-morpholin-4-ylimidazolidin-2-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)NC(N2CCOCC2)C1 ADOLLNOHUDQRCE-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000013409 limited attention Diseases 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19721580A DE19721580A1 (de) | 1997-05-23 | 1997-05-23 | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
PCT/DE1998/001343 WO1998052548A2 (fr) | 1997-05-23 | 1998-05-14 | Utilisation de 1-ar(alk)yl-imidazolin-2-one pour le traitement de l'angoisse et du stress |
US09/079,802 US5994347A (en) | 1997-05-23 | 1998-05-15 | For a process for treatment of anxiety and tension |
Publications (3)
Publication Number | Publication Date |
---|---|
NO995300L NO995300L (no) | 1999-10-29 |
NO995300D0 NO995300D0 (no) | 1999-10-29 |
NO325346B1 true NO325346B1 (no) | 2008-04-07 |
Family
ID=26036759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19995300A NO325346B1 (no) | 1997-05-23 | 1999-10-29 | Anvendelse av 1-ar(alk)yl-imidazolin-2-on for behandling av angst- og spenningstilstander |
Country Status (25)
Country | Link |
---|---|
US (1) | US5994347A (fr) |
EP (1) | EP0979083B1 (fr) |
JP (1) | JP4838403B2 (fr) |
CN (1) | CN1150901C (fr) |
AR (1) | AR012746A1 (fr) |
AT (1) | ATE246926T1 (fr) |
AU (1) | AU745536B2 (fr) |
BG (1) | BG63378B1 (fr) |
BR (1) | BR9809666A (fr) |
CA (1) | CA2291075C (fr) |
DE (2) | DE19721580A1 (fr) |
DK (1) | DK0979083T3 (fr) |
ES (1) | ES2205516T3 (fr) |
HU (1) | HUP0003108A3 (fr) |
IL (1) | IL132652A0 (fr) |
NO (1) | NO325346B1 (fr) |
NZ (1) | NZ500849A (fr) |
PL (1) | PL193589B1 (fr) |
PT (1) | PT979083E (fr) |
RU (1) | RU2203055C2 (fr) |
SK (1) | SK284258B6 (fr) |
TR (1) | TR199902815T2 (fr) |
TW (1) | TW579294B (fr) |
WO (1) | WO1998052548A2 (fr) |
ZA (1) | ZA984197B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL166593A0 (en) | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
US20050070537A1 (en) | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
CA2531861A1 (fr) * | 2003-07-11 | 2005-01-20 | Elbion Ag | Methode de traitement ou de prevention de troubles du systeme nerveux central au moyen de composes a selectivite pour la sous-unite alpha 3 du recepteur des benzodiazepines |
CA2576344C (fr) | 2004-08-11 | 2010-10-05 | Cadbury Adams Usa Llc | Compositions de rechauffement et systemes de liberation associes |
US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4044021A (en) * | 1971-10-21 | 1977-08-23 | American Cyanamid Company | Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism |
DE19532668A1 (de) * | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
US5869481A (en) * | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
-
1997
- 1997-05-23 DE DE19721580A patent/DE19721580A1/de not_active Withdrawn
-
1998
- 1998-05-14 NZ NZ500849A patent/NZ500849A/en unknown
- 1998-05-14 CA CA002291075A patent/CA2291075C/fr not_active Expired - Lifetime
- 1998-05-14 DK DK98933532T patent/DK0979083T3/da active
- 1998-05-14 EP EP98933532A patent/EP0979083B1/fr not_active Expired - Lifetime
- 1998-05-14 ES ES98933532T patent/ES2205516T3/es not_active Expired - Lifetime
- 1998-05-14 WO PCT/DE1998/001343 patent/WO1998052548A2/fr active IP Right Grant
- 1998-05-14 HU HU0003108A patent/HUP0003108A3/hu unknown
- 1998-05-14 AT AT98933532T patent/ATE246926T1/de not_active IP Right Cessation
- 1998-05-14 AU AU83326/98A patent/AU745536B2/en not_active Expired
- 1998-05-14 CN CNB988053748A patent/CN1150901C/zh not_active Expired - Lifetime
- 1998-05-14 BR BR9809666-4A patent/BR9809666A/pt not_active Application Discontinuation
- 1998-05-14 IL IL13265298A patent/IL132652A0/xx not_active IP Right Cessation
- 1998-05-14 PT PT98933532T patent/PT979083E/pt unknown
- 1998-05-14 JP JP54979698A patent/JP4838403B2/ja not_active Expired - Lifetime
- 1998-05-14 RU RU99128109/14A patent/RU2203055C2/ru active
- 1998-05-14 TR TR1999/02815T patent/TR199902815T2/xx unknown
- 1998-05-14 DE DE59809285T patent/DE59809285D1/de not_active Expired - Lifetime
- 1998-05-14 SK SK1584-99A patent/SK284258B6/sk not_active IP Right Cessation
- 1998-05-14 PL PL98337090A patent/PL193589B1/pl not_active IP Right Cessation
- 1998-05-15 US US09/079,802 patent/US5994347A/en not_active Expired - Lifetime
- 1998-05-19 ZA ZA9804197A patent/ZA984197B/xx unknown
- 1998-05-20 TW TW087107848A patent/TW579294B/zh not_active IP Right Cessation
- 1998-05-22 AR ARP980102409A patent/AR012746A1/es not_active Application Discontinuation
-
1999
- 1999-10-29 NO NO19995300A patent/NO325346B1/no not_active IP Right Cessation
- 1999-11-04 BG BG103859A patent/BG63378B1/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4817495B2 (ja) | 外因性カンナビノイドでの痛みの制御 | |
Yokoyama et al. | Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats | |
Sandrini et al. | Effect of rofecoxib on nociception and the serotonin system in the rat brain | |
AU2018253600B2 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
Schmoutz et al. | Antagonism of the neuropeptide S receptor with RTI-118 decreases cocaine self-administration and cocaine-seeking behavior in rats | |
Gao et al. | Antinociceptive effects of sinomenine combined with ligustrazine or paracetamol in animal models of incisional and inflammatory pain | |
US20020091075A1 (en) | Treatment of depression | |
NO325346B1 (no) | Anvendelse av 1-ar(alk)yl-imidazolin-2-on for behandling av angst- og spenningstilstander | |
Loutochin et al. | Effect of the anticonvulsant medications pregabalin and lamotrigine on urodynamic parameters in an animal model of neurogenic detrusor overactivity | |
Gabra et al. | mGluR5 antagonists that block calcium mobilization in vitro also reverse (S)-3, 5-DHPG-induced hyperalgesia and morphine antinociceptive tolerance in vivo | |
Yin et al. | Latent sex differences in CaMKII-nNOS signaling that underlie antidepressant-like effects of yueju-ganmaidazao decoction in the Hippocampus | |
Gupta et al. | Anti-inflammatory activity of sodium pyruvate-a physiological antioxidant | |
KR100577626B1 (ko) | 1-아르(알크)일-이미다졸린-2-온을 포함하는, 불안 치료용 약제학적 조성물 | |
dos Santos Leite et al. | Effects of Dexamethasone, Clonidine, Tramadol and Nalbuphine on Fentanyl-Induced Hyperalgesia in Rats | |
Ahtee et al. | The fall of homovanillic acid and 5-hydroxyindoleacetic acid concentrations in brains of mice withdrawn from repeated morphine treatment and their restoration by acute morphine administration | |
MXPA99010609A (en) | Use of 1-ar(alk)yl-imidazolin-2-one for treating anxiety and stress conditions | |
EP1645270B1 (fr) | Elimination de la douleur au moyen d'anandamide | |
dos Santos Leite et al. | Effects of Ketoprofen, Ketamine, Lidocaine and Propofol on Fentanyl-Induced Hyperalgesia in Rats | |
CN104936584A (zh) | 用于行为、精神和认知障碍的预防和治疗的组合物 | |
OA20556A (en) | Treatment for synucleinopathies | |
Airaksinen et al. | Alpha₂-adrenoceptor antagonists: new ways to influence attention and memory | |
CZ296188B6 (cs) | 1-Ar(alk)ylimidazolin-2-on pro osetrování stavu úzkosti a napetí | |
Oxenkrug et al. | Central but not peripheral benzodiazepine agonists attenuate clorgyline effect on melatonin synthesis | |
Valdman et al. | Membrane-related effects of antidepressant drugs on synaptosomal membranes of intact rats and animals with modeled behaviour depression | |
Bennion et al. | Neuroprotection by Post-Stroke Administration of an Oral Formulation of |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |